BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, July 6, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Regulatory actions for Jan. 18, 2022

Jan. 18, 2022

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Algernon, Glenmark, Novartis, Numinus, Pfizer.


Read More

Other news to note for Jan. 18, 2022

Jan. 18, 2022
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Almirall, Amagma, Artizan, Bayer, Betterlife, Celmatix, Claritas, Cosette, Cybin, Cytoimmune, Daiichi Sankyo, Endo, Endosane, Eracal, Evelo, Evgen, Evotec, Feldan, Filament, Immuron, Innovent, IRB Barcelona, J&J, Kyowa Kirin, Lantern, Lava, Leyden, Merck & Co., Mindrank, Neurimmune, Novo Nordisk, Nrx, Ono, Poolbeg, Praxis, Ridgeback, Qualigen, Vanda, Virpax, Wesana.
Read More
Henley Ion Virus Defender device

New Orleans device firm reveals high hopes for COVID defense tech

Jan. 14, 2022
By Catherine Longworth
Henley Ion Inc. is encouraged by early testing of a COVID-19 protection device. Henley’s Ion Virus Defender technology uses micronized electrostatic precipitation (mEP) to remove infectious bioaerosols from both inhaled and exhaled air. The company said initial tests of the prototype removed 99.8% of SARS-CoV-2 bioaerosols under Biosafety Level 3 testing conditions.
Read More
Pills spilling out of prescription bottle

Everest acquires rights to 3CL protease inhibitors to develop antivirals for COVID-19

Jan. 14, 2022
By David Ho
Shanghai-based Everest Medicines Ltd. has won exclusive global rights to a set of viral 3C-like (3CL) protease inhibitors from Singapore's national drug discovery platform, the Experimental Drug Development Centre (EDDC), in a deal worth up to $214.5 million.
Read More
Patrick Doyle, CEO, Kbio Holdings Ltd.
Newco news

BAT follows tobacco rival Philip Morris into biotech, promising faster R&D with Kbio’s plant-based tech

Jan. 14, 2022
By Richard Staines
Following Philip Morris International Inc.’s controversial takeover of respiratory drug firm Vectura plc, British American Tobacco plc (BAT) is also making inroads into medical research with U.K.-based Kbio Holdings Ltd., a biotech focused on plant-based medicine.
Read More

In the clinic for Jan. 14, 2022

Jan. 14, 2022
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adagene, AI, Ascletis, First Wave, Gritstone, GSK, Imcyse, Oncopeptides, On Target, Redhill, Rhythm, Rubius, Spago, Tempus.
Read More
U.S. flag and White House podium

Biden administration boosts at-home COVID-19 test purchase to 1B

Jan. 13, 2022
By Annette Boyle
In a speech on Jan. 13, President Joe Biden revealed plans to purchase an additional 500 million at-home COVID-19 tests, bringing the total number the administration expects to provide for free to American households to 1 billion. In addition, Biden said the administration would distribute free “high quality masks.” On Wednesday, the administration said it would provide 5 million rapid COVID-19 tests and 5 million lab-based PCR tests to schools each month to support screening testing and test-to-stay programs.
Read More
Pregnancy

Study tracking pregnancies shows increased risk of COVID-19 complications for the unvaccinated

Jan. 13, 2022
By Nuala Moran
LONDON – A population level study tracking every pregnancy in Scotland between the start of the pandemic in March 2020 and the end of October 2021 lays bare the devastating impact of COVID-19 on perinatal mortality.
Read More

Regulatory actions for Jan. 13, 2022

Jan. 13, 2022

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abivax, Ascendis, Atai, Basilea, Cellular, Denali, Edesa, GSK, Hutchmed, Jeil, Mitsubishi, Novavax, Pharmather, Rockwell, SK, Vir.


Read More

Other news to note for Jan. 13, 2022

Jan. 13, 2022
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Accuredit, Adagio, Advanz, Allecra, Amgen, Atyr, Bridgebio, Bristol Myers Squibb, Can-Fite, Captor, Endo, Halberd, Helmholtz , ITM, Journey Medical, Lysogene, N1, Prellis, Radius Health, Sarepta, Vir, Vyne, Zhittya.
Read More
Previous 1 2 … 143 144 145 146 147 148 149 150 151 … 553 554 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 2, 2026.
  • AI-generated image for brain organoid neural research

    CINP 2026: organoids reveal autism and addiction mechanisms

    BioWorld Science
    At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
  • CINP 2026: Prenatal and adolescent stress shape brain vulnerability

    BioWorld Science
    Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
  • Ontrack Therapeutics divulges compounds for neurodegenerative diseases

    BioWorld Science
    Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
  • Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists

    BioWorld Science
    Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing